Good Manufacturing Practice and Validation

[1]  S. Martins,et al.  Purification of a cystic fibrosis plasmid vector for gene therapy using hydrophobic interaction chromatography , 2000, Biotechnology and bioengineering.

[2]  O Doblhoff-Dier,et al.  Quality control and assurance from the development to the production of biopharmaceuticals. , 1999, Trends in biotechnology.

[3]  J. Kaiser,et al.  As Gelsinger Case Ends, Gene Therapy Suffers Another Blow , 2005, Science.

[4]  D. Sherratt,et al.  Escherichia coli strains that allow antibiotic-free plasmid selection and maintenance by repressor titration. , 2001, Nucleic acids research.

[6]  O. Cohen-Haguenauer.  Gene therapy: regulatory issues and international approaches to regulation. , 1997, Current opinion in biotechnology.

[7]  D. Prazeres,et al.  Analysis and use of endogenous nuclease activities in Escherichia coli lysates during the primary isolation of plasmids for gene therapy. , 1999, Biotechnology and bioengineering.

[8]  Magda Marquet,et al.  Process development for the manufacture of plasmid DNA vectors for use in gene therapy , 1996 .

[9]  Anne M. Baldeshwiler.  History of FDA good laboratory practices , 2003 .

[10]  Möller Al.  Clean room technologies of the 1990s. , 1992 .

[11]  E. Griffiths,et al.  WHO guidelines for assuring the quality of DNA vaccines. , 1998, Biologicals : journal of the International Association of Biological Standardization.

[12]  J. Lown,,et al.  Rational recognition of nucleic acid sequences. , 1999, Current opinion in biotechnology.

[13]  B Junker.  Technical evaluation of the potential for streamlining of equipment validation for fermentation applications. , 2001, Biotechnology and bioengineering.

[14]  E. Flaschel,et al.  Production of Recombinant RNase Ba and Its Application in Downstream Processing of Plasmid DNA for Pharmaceutical Use , 2006, Biotechnology progress.

[15]  Stephen Wessels,et al.  Microbial Cell Factories BioMed Central Review Ensuring safety of DNA vaccines , 2005 .

[16]  G Sofer,et al.  Validation of biotechnology products and processes. , 1995, Current opinion in biotechnology.

[17]  C L Cooney,et al.  Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks. , 1999, Trends in biotechnology.

[18]  John G. Grazal,et al.  EU and FDA GMP regulations: overview and comparison , 1997 .

[19]  Raf Lemmens,et al.  Plasmid DNA purification , 2004 .

[20]  Michel Sadelain,et al.  Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies. , 2007, Vaccine.

[21]  Janice E. Boyd.  Facilities for Large‐Scale Production of Vectors under GMP Conditions , 2001 .

[22]  M. Schleef,et al.  Plasmid DNA for clinical phase I and II studies. Large-scale cGMP manufacturing and quality assurance. , 1998, Advances in experimental medicine and biology.

[23]  Christoph Berger,et al.  Use of substances of animal origin in pharmaceutics and compliance with the TSE-risk guideline -- a market survey. , 2005, Biologicals : journal of the International Association of Biological Standardization.

[24]  R. Necina,et al.  Automated alkaline lysis for industrial scale cGMP production of pharmaceutical grade plasmid-DNA. , 2007, Journal of biotechnology.